Alector soars on Genentech deal for experimental Parkinson's drug

By Reuters News

** Shares of drug maker Alector ALEC.O surge 44.20% to $2.61 premarket

** Co enters global licensing deal with Genentech for AL050, ALEC's experimental drug for Parkinson's disease

** ALEC grants Genentech exclusive global rights to develop and commercialize AL050

** The deal brings $100 million upfront and is eligible for up to $1.17 billion in milestone payments into 2029 - ALEC

** Co retains ownership of its ABC platform, its technology platform for developing neurodegenerative disease therapies, and full rights for pipeline use

** As of last close, ALEC up 16.03%

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk